220 results about "Cord blood" patented technology

The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl). More particularly, this invention provides an agonist antibody to a human thrombopoietin receptor, wherein the agonist antibody comprises: antibody constant regions comprising (1) amino acid sequences in a heavy chain constant region and a light chain constant region of a human antibody, (2) an amino acid sequence of a heavy chain constant region with a domain substituted between human antibody subclasses, and an amino acid sequence of a light chain constant region of a human antibody, or (3) amino acid sequences comprising a deletion(s), substitution(s), addition(s), or insertion(s) of one or several amino acid residues in the amino acid sequences of (1) or (2) above; and antibody variable regions capable of binding to and activating a human thrombopoietin receptor; and wherein the agonist antibody has the properties: (a) that the antibody induces colony formation at a concentration of 10,000 ng/ml or lower as determined by the CFU-MK colony formation assay using human umbilical-cord-blood-derived CD34+ cells; and (b) that the antibody has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less in the cell proliferation assay using UT7/TPO cell. Also provided is a pharmaceutical composition for treating thrombocytopenia comprising said antibody.

The invention relates to a method for separating exosome from a human umbilical cord mesenchymal stem cell source and a reagent used by the method. The method comprises the following steps: (1) cultivating umbilical cord mesenchymal stem cells; and (2) extracting umbilical cord blood MSC exosome, wherein the umbilical cord mesenchymal stem cells are cultivated to P3 generation; and extraction forthe umbilical cord blood MSC exosome comprises the following steps: pre-treating exosome suspension; and extracting exosome. The reagent used by the method realtes to a solution which has a special formula and is used as a buffer pad. The method has the excellent technical effects as described in the specification.

Populations of stem cells and methods for their isolation and use are provided. These stem cell populations comprise aldehyde dehydrogenase positive (ALDH^br) cells isolated from bone marrow, and ALDH^br CD105⁺ cells derived from any stem cell source. These populations may also comprise cells expressing such surface markers as CD34, CD38, CD41, CD45, CD105, CD133, CD135, CD117, and HLA-DR, and/or are substantially free from such cell surface markers as CD3, CD7, CD 10, CD 13, CD 14, C1319, CD33, CD35, CD56, CD 127, CD 138, and glycophorin A. The population may also comprise cells expressing CD90. The stem cell populations of the invention are isolated from a stem cell source such as bone marrow, peripheral blood, umbilical cord blood, and fetal liver. Methods of the invention comprise isolating and purifying stem cell populations from stem cell sources, and methods of using these cells to reconstitute, repair, and regenerate tissues.

The invention relates to an in vitro amplification and low-temperature storage method for regulatory T cells of umbilical cord blood. The method comprises the following steps of: separating a CD4+CD25+T cell group rich in the regulatory T cells from the umbilical cord blood; amplifying the enriched CD4+CD25+T cell group to obtain high-purity regulatory T cells; and storing the amplified regulatory T cells in liquid nitrogen at a low temperature to serve as third-party unrelated donor regulatory T cells for treating clinical diseases. The method has the advantages that: a large quantity of regulatory T cells can be obtained from the umbilical cord blood and stored for a long term in the liquid nitrogen, can meet the requirements of clinic for regulatory T cell products, and are used for treating graft versus host disease, organ transplantation rejection and autoimmune disease.

The invention discloses freezing storage protective solution for a human umbilical Wharton's jelly tissue block. 1 liter of the freezing storage protective solution comprises 0.8 to 1.2 mol of glycol, 0.4 to 0.6 mol of dimethyl sulfoxide, 0.1 to 0.3 mol of cane sugar, 100 to 200 milliliters of cord blood autoserum and the balance of culture solution DMEM/F12. In the freezing storage protective solution, the cord blood autoserum and the culture solution DMEM/F12 serve as base solution to provide nutrient for the tissue block, so osmotic equilibrium inside and outside cells is guaranteed, the cell environment in the tissue block is guaranteed to be similar to the in vivo environment, and the freezing storage effect is good; the low-concentration glycol and dimethyl sulfoxide serve as a permeability freezing protective agent, so the toxicity of the freezing storage protective solution to the cells is reduced; and the cane sugar serves as a non-permeability freezing protective agent, so the viscosity of the solution is increased and the osmotic pressure inside and outside cell membranes is relieved when the cells are frozen and stored. The human umbilical Wharton's jelly tissue block can be directly frozen and stored by the freezing storage protective solution, so the freezing storage effect is good, the cell damage is little, and high-quality human umbilical mesenchymal stem cells can be provided for clinic.

The invention relates to a medical device, in particular to a lumbar booster physiotherapy cord which can cure and ease diseases such as human sciatic nerve, lumbar muscle strain, and lumbar disc protrusion, etc. The cord body is bonded with the four sides of an airbag cavity in the thermal sealing way. Lumbar acupoint magnetic blocks are vertically arranged in the two sides of the central lumbar of the airbag pasted on the body. A traditional Chinese drug bag is crossly arranged on the two sides of the central lumbar of the airbag pasted on the body. The output pipe of an airbag switch is connected with the cord body. The input end of the airbag switch is connected with a gas space through a rubber hose. The gas space is provided with an adjustable pressure maintaining valve and a release valve and a micro-air compressor which are communicated with the gas space. The lumbar booster physiotherapy cord is provided with the airbag cavity which can play the roles of support and massage. The medication point and the magnetic therapy point provided by the lumbar booster physiotherapy cord can play the function of nourishing the kidney and activating the blood flow in order to cure a plurality of lumbar diseases quickly. The lumbar booster physiotherapy cord is suitable for the cure and the ease of the human lumbar diseases.

The invention relates to an exosome preparation prepared from umbilical cord blood bone marrow mesenchymal stem cells, and a preparation method of the exosome preparation. The exosome is obtained froma cell culture containing at least 10<4> cells. When the cell culture reaches fusion, washing is performed in PBS, a KO-DMEM culture medium is added and the cell culture is put back into an incubatorcontaining carbon dioxide for culture, the cell culture is cultured for 2-20 days, and the exosome is prepared through the ultracentrifugation technology, size exclusion filtration, chemical precipitation, discontinuous density gradient, immunoaffinity, ultrafiltration and/or high performance liquid chromatography, and preferably through PEG precipitation. The exosome prepared by the method is stable, high in purity, and comprehensive in positive markers, and can be used for activating proliferation and regeneration, promoting wound healing, and other medical clinical uses.

The invention discloses a method for freezing DC cells and CIK seed cells in blood, and the prepared cells and their application. The mononuclear cells in peripheral blood or umbilical cord blood are frozen in autologous serum after appropriate treatment, and the cell The cryoprotectant makes the survival rate of the cells reach 80%. The resuscitated cells can be used to prepare DC-cells and CIK cells at the same time, and finally prepare DC-CIK cell preparations that can meet the needs of clinical applications. In this way, the requirement of multiple DC-CIK clinical treatments can be realized in a single blood collection, thus providing support for the large-scale development of immune cell therapy.

The invention provides a DC-CIK co-culture cell preparation method. According to the invention, mononuclear cells separated from umbilical cord blood are separately differentiated into DC cells and CIK cells, and then the DC cells and the CIK cells are co-cultured; and mature DC cells are obtained through two-stage differentiation of the mononuclear cells separated from umbilical cord blood in virtue of a plurality of factors. The DC-CIK co-culture cell preparation method provided by the invention shortens time needed for obtainment of the mature DC cells by at least two folds and improves DC-CIK cell co-culture efficiency.

The invention relates to the field of stem cell biology, and discloses a preparation method of natural killer cells differentiated from human pluripotent stem cells. The preparation method comprises the steps of S1, forming an embryoid body; S2, performing directional permanent hematopoiesis differentiation on the embryoid body to obtain hematopoietic precursor cells; and S3, differentiating the hematopoietic precursor cells to obtain natural killer cells. The invention also discloses application of the natural killer cell prepared by the method as a pharmaceutical composition for preventing and/or treating tumors by cells. According to the method, efficient and stable differentiation of the NK cells is achieved, EB adherent differentiation is achieved in the induced differentiation period, TGFB inhibitor treatment is prolonged, 10% or above of CD34+CD45+permanent hematopoietic HPCs can be obtained through rapid induction. The method has the advantages of being efficient, stable, low in cost and suitable for large-scale cell preparation production; and the method is easy and convenient to operate, the NK cells obtained through differentiation have typical NK cell surface marking molecules, the anti-tumor function of the NK cells is superior to that of the NK cells derived from umbilical cord blood, and great scientific research and clinical application potentials are achieved.

The invention provides a culture method for monkshood polysaccharide-induced nature killer T cell (Nature Killer T cell, NKT) proliferation. The method comprises the characteristics as follows: human peripheral blood, marrow or a mononuclear cell with an umbilical cord blood source are continuously cultivated by traditional Chinese medicine monkshood polysaccharide and recombinant human interleukin 2, a lot of nature kill T cells are obtained, NK<1.1+> and CD<8+> are expressed, interferon gamma is secreted, the ratio in lymphocyte at the 14th day is more than 16.15%, the order of magnitude can be up to over 5*10<9>, and the nature kill T cell have effective anti-tumor and anti-virus functions. A clinical application of the NKT cell obtained by the method is also provided by the invention.

The present invention relates to mainly one system of efficient culturing and directive inducing stem cell differentiation for culturing and proliferating megakaryocyte. The system has umbilical cord blood and marrow stem cell as seed cell, and the serum-free culture medium comprising TPO, IL-11 and heparin as the main component for megakaryocyte proliferation. The megakaryocyte preparation prepared based on the present invention contains great amount of macronucleus ancestral cells and mature megakaryocyte as well as CD34+ cells, and has the functions of treating thrombocytopenia and improving the blood-forming function after stem cell transplantation. The present invention provides novel efficient cell treating preparation for various thrombocytopenia and hemocyitopenia.

The invention discloses a cell factor, the cell factor is prepared through the following steps: (1) processing primary stroma cells; (2) obtaining immortalized cells; (3) subjecting the fetal hepatocytes selected in the step (2) to continuous subculture to obtain a cell line; (4) obtaining a total RNA; (5) carrying out an inverse transcription process to convert the total RNA into cDNA; (6) carrying out a gene chip analysis; (7) selecting the high-expression gene sequence, which can promote the in-vitro amplification of umbilical cord blood hematopoietic stem cells, from the rat fetal hepatocytes; (8) retrieving the nucleotide sequence obtained in the step (7); (9) obtaining a 293T cell; (10) obtaining a corresponding protein of the 293T cell; (11) adding the purified protein obtained in the step (10) into a StemSpan culture medium containing SCF, TPO, FLT3L, and PTN, and testifying the promotion effect on the in-vitro amplification of umbilical cord blood hematopoietic stem cells. The cell factor has the advantages of prominent increasing on amplification multiple of umbilical cord blood hematopoietic stem cells and maintenance of stem cell characteristics.

The invention discloses an umbilical artery para-aortic stem cell injection for treating an ischemic disease and a preparation method thereof. The injection comprises suspended umbilical artery para-aortic stem cells and a solvent. The solvent may be platelet-rich umbilical cord plasma or PBS for injection containing human serum albumin. The preparation method comprises the steps of after umbilical artery tissue culture, deriving the artery para-arterial stem cells, enzymatically digesting to obtain single umbilical artery para-aortic stem cell, washing twice with PBS, and then gently mixing with the solvent to obtain the umbilical artery para-arterial stem cell injection. The cells are taken from a medical waste umbilical cord and have the advantages of easy separation, rapid proliferation and low immunogenicity. The PBS containing the 5% human serum albumin or the platelet-rich umbilical cord plasma resuspends the umbilical artery para-arterial stem cells to prepare the injection suspension, and the suspension is injected to significantly improve the blood supply of lower limb ischemia model mice.

The invention belongs to the technical field of immune cell in-vitro culture, and particularly discloses a culture method of umbilical cord blood lymphocyte CIK. The method comprises the following steps: by using umbilical cord blood as a treatment object, separating the umbilical cord blood mononuclear cells, purifying and inducing the CIK cells, culturing and amplifying the CIK cells, and finally, centrifuging to collect the mature umbilical cord blood CIK cells, thereby obtaining the product. The IFN-gamma and alpha-galactose ceramide are added to activate the CIK cells, and CD3 monoclonalantibodies, IL-1 alpha, IL-2 and IL-1 beta are added in the early culture stage to perform continuous stimulation, thereby saving the coating time and enhancing the activation efficiency and amplification efficiency of effector cell groups.